Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations

Journal of Infectious Diseases

Volumn 204, Issue 3, 2011, Pages 340-347

  Holmes, Natasha E ^a   Turnidge, John D ^b,c   Munckhof, Wendy J ^d,e   Robinson, James O ^f   Korman, Tony M ^g,h   O'Sullivan, Matthew V N ⁱ   Anderson, Tara L ⁱ   Roberts, Sally A ^b   Gao, Wei ^a   Christiansen, Keryn J ^f,j   Coombs, Geoffrey W ^f   Johnson, Paul D R ^a,g,k   Howden, Benjamin P ^a,g,k  

^a AUSTIN HEALTH   (Australia)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f ROYAL PERTH HOSPITAL   (Australia)

^g MONASH UNIVERSITY   (Australia)

^h Southern Health ^*  (Australia)

ⁱ UNIVERSITY OF TASMANIA   (Australia)

^j UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^k UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; FLUCLOXACILLIN; METICILLIN; VANCOMYCIN;

ADULT; AGE; AGED; ARTICLE; AUSTRALIA AND NEW ZEALAND; BACTERIUM ISOLATION; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CHOICE; DRUG FATALITY; EPSILOMETER TEST; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS BACTEREMIA; MICROBIOLOGICAL PARAMETERS; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; PATIENT ASSESSMENT; PRIORITY JOURNAL; STAPHYLOCOCCAL BACTEREMIA; TREATMENT OUTCOME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 79960135233     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir270     Document Type: Article

References (31)

1. Jensen AG, Wachmann CH, Espersen F, Scheibel J, Skinhoj P, Frimodt-Moller N. Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. Arch Intern Med 2002; 162:25-32. (Pubitemid 34073396)
2. Wang JL, Chen SY, Wang JT, et al. Comparison of both clinical features and mortality risk associated with bacteremia due to communityacquired methicillin-resistant Staphylococcus aureus and methicillinsusceptible S. aureus. Clin Infect Dis 2008; 46:799-806.
3. Malani PN, Rana MM, Banerjee M, Bradley SF. Staphylococcus aureus bloodstream infections: the association between age and mortality and functional status. J Am Geriatr Soc 2008; 56:1485-9.
4. Shurland S, Zhan M, Bradham DD, Roghmann MC. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol 2007; 28:273-9. (Pubitemid 46480725)
5. Turnidge JD, Kotsanas D, Munckhof W, et al. Staphylococcus aureus bacteremia: a major cause of mortality in Australia and New Zealand. Med J Aust 2009; 191:368-73.
6. Kim SH, Kim KH, Kim HB, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008; 52:192-7.
7. Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003; 82:333-9. (Pubitemid 37229468)
8. Siegman-Igra Y, Reich P, Orni-Wasserlauf R, Schwartz D, Giladi M. The role of vancomycin in the persistence or recurrence of Staphylococcus aureus bacteremia. Scand J Infect Dis 2005; 37:572-8.
9. Stryjewski ME, Szczech LA, Benjamin DK Jr, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007; 44:190-6. (Pubitemid 46079979)
10. Lodise TP Jr,McKinnon PS, Levine DP, Rybak MJ. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:3731-3. (Pubitemid 47519366)
11. Gentry CA, Rodvold KA, Novak RM, Hershow RC, Naderer OJ. Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy 1997; 17:990-7. (Pubitemid 27415102)
12. Chang FY, MacDonald BB, Peacock JE Jr, et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 2003; 82:322-32. (Pubitemid 37229467)
13. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. Highdose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138-44. (Pubitemid 44631403)
14. Khatib R, Johnson LB, Sharma M, Fakih MG, Ganga R, Riederer K. Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time. Scand J Infect Dis 2009; 41:4-9.
15. Musta AC, Riederer K, Shemes S, et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 2009; 47: 1640-4.
16. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52:3315-20.
17. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193-200. (Pubitemid 351269157)
18. Hsu DI, Hidayat LK, Quist R, et al. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents 2008; 32:378-85.
19. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398-402. (Pubitemid 38747480)
20. Wang JL, Wang JT, Sheng WH, Chen YC, Chang SC. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC 5 2 mg/L, by the broth microdilution method. BMC Infect Dis 2010; 10:159.
21. Cosgrove SE, Fowler VG Jr. Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46(Suppl 5):S386-93.
22. Bannerman TL, Peacock SJ. Staphylococci, micrococci, and other catalase-positive organisms. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. 9th ed. Washington, DC: ASM Press, 2007.
23. Clinical Laboratory and Standards Institute (CLSI). Performance standards for antimicrobial disk susceptibility tests: approved standard, 10th ed. CLSI document M02-A10. Wayne, PA: CLSI, 2009.
24. Clinical Laboratory and Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard, 8th ed. CLSI document M07-A8. Wayne, PA: CLSI, 2009.
25. O'Brien FG, Udo EE, Grubb WB. Contour-clamped homogeneous electric field electrophoresis of Staphylococcus aureus. Nat Protoc 2007; 1:3028-33.
26. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr.. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38:1700-5. (Pubitemid 38781661)
27. Lodise TP, Miller CD, Graves J, et al. Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteremia. J Antimicrob Chemother 2008; 62:1138-41.
28. Moise PA, Smyth DS, El-Fawal N, et al. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteremia. J Antimicrob Chemother 2008; 61:85-90.
29. Robinson JO, Pearson JC, Christiansen KJ, Coombs GW, Murray RJ. Community-associated versus healthcare-associated methicillinresistant Staphylococcus aureus bacteremia: a 10-year retrospective review. Eur J Clin Microbiol Infect Dis 2009; 28:353-61.
30. Price J, Atkinson S, Llewelyn M, Paul J. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin Infect Dis 2009; 48:997-8.
31. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycinintermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23:99-139.